[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350745-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350745-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","distinguishing-ki67-stratification-expression-in-er-positiveher2-negative-breast-cancers-comparison-of-advanced-mri-diffusion-models","Distinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers - comparison of advanced MRI diffusion models","","This diagnostic retrospective study evaluates advanced MRI diffusion-derived first-order features for discriminating Ki67 expression in ER+/HER2- invasive ductal breast cancer. It includes 121 patients undergoing conventional DWI, diffusion kurtosis imaging (DKI), fractional order calculus (FROC), and continuous-time random walk (CTRW). Ki67 is pathologically grouped into low (≤5%), medium (>5% to \u003C30%), and high (≥30%). Sixty-three diffusion parameters are compared with ROC-AUC, and optimal models are built using multivariate logistic regression with bootstrap validation; the FROC model improves low Ki67 identification for clinical decision support.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/distinguishing-ki67-stratification-expression-in-er-positiveher2-negative-breast-cancers-comparison-of-advanced-mri-diffusion-models/350745/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/distinguishing-ki67-stratification-expression-in-er-positiveher2-negative-breast-cancers-comparison-of-advanced-mri-diffusion-models/350745.png","ImageObject",300,407,{"name":42,"@type":43},"LangkahRina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of distinguishing Ki67 stratification expression in ER+/HER2- breast cancer?","Question",{"text":63,"@type":64},"Ki67 stratification guides clinical treatment strategy decisions and helps predict patient outcomes. The study focuses on improving diagnostic discrimination of Ki67 expression levels using MRI-derived features.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients grouped by Ki67 expression in this study?",{"text":68,"@type":64},"Patients were pathologically categorized into low (≤5%, n=30), medium (>5% to \u003C30%, n=41), and high Ki67 expression groups (≥30%, n=50).",{"name":70,"@type":61,"acceptedAnswer":71},"Which MRI-based model showed the best performance for identifying low Ki67 expression?",{"text":72,"@type":64},"The FROC model constructed by D10%, µ90% and µSkewness achieved optimal diagnostic efficacy (AUC=0.858) and outperformed the conventional DWI model for low Ki67 discrimination.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350745,1790189026,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Kang et al. BMC Medical Imaging (2026) 26:427 BMC Medical Imaging  \n[https://doi.org/10.1186/s12880-026-02338-8](https://doi.org/10.1186/s12880-026-02338-8)  \nRESEARCH Open Access  \nDistinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers: comparison of advanced MRI diffusion models  \nZhongqi Kang1,5†, Siyao Du1†, Li Zhao1†, Ruimeng Zhao1, Si Gao2, Yanni Zhang1,5, Jiaping Yu1,5, Xiaofei Liu 1, Yueluan Jiang3, Yan Wang4* and Lina Zhang1,5*  \nAbstract  \nPurpose Identifying the stratification expression of Ki67 is crucial for directing clinical treatment strategies in ER+/ HER2-breast cancers. This diagnostic study investigated the value of first-order features extracted from conventional DWI, diffusion kurtosis imaging (DKI), fractional order calculus (FROC), and continuous-time random walk (CTRW) in discriminating Ki67 expression of ER+/HER2-invasive ductal breast cancer.  \nMaterials and methods This retrospective study included 121 patients who underwent DWI, DKI, FROC and CTRWand were pathologically categorized into the low (≤ 5%, n = 30), medium (> 5% to \u003C 30%, n = 41), and high Ki67 expression group (≥ 30%, n = 50) . Sixty-three diffusion parameters were computed and subsequently compared across different groups. The area under the receiver operating characteristic (ROC) curve (AUC) was used to quantify diagnostic efficacy. Multivariate logistic regression and bootstrap (1,000 samples) analyses were used to establish and evaluate, respectively, the optimal model to identify Ki67 expression.  \nResults Twenty-three features showed statistically significant differences among the low, medium and high expression groups (all p values \u003C 0. 05) . Further multivariable logistic regression analysis for discriminating the low Ki67 and non-low expression group showed that the FROC model constructed by D 10%, µ90% and µSkewness had optimal diagnostic efficacy (AUC = 0 . 858; 95% confidence interval, 0 .783–0. 915), which was significantly better than that of DWI model (AUC = 0 . 677; p = 0 . 008) . The validation model showed good accuracy (AUC = 0 . 850; 95%CI, 0 .774–0. 916) . Conclusions The FROC model could help identify the low Ki67 expression (≤ 5%) and prevent unnecessary chemotherapy.  \nKeywords Breast neoplasms, Magnetic resonance imaging, Diffusion-weighted MRI  \n†Zhongqi Kang, Siyao Du and Li Zhao contributed equally to this work.  \n*Correspondence: Yan Wang [18602441616@163.com](18602441616@163.com)[ ](18602441616@163.com)Lina Zhang [lnzhang@cmu.edu.cn](lnzhang@cmu.edu.cn)  \n1Department of Radiology, The First Hospital of China Medical University, Shenyang, Liaoning Province 110001, China  \n2Department of Intervention, The First Hospital of China Medical University, Shenyang 110001, China  \n3MR Research Collaboration, Siemens Healthineers, Beijing 100102, China 4Department of Pathology, The First Hospital of China Medical University, Shenyang, Liaoning Province 110001, China  \n5Department of Radiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning Province 110165, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obt","cbCaitw224aaJODD","https://ap.wps.com/l/cbCaitw224aaJODD","pdf",2210328,14,"English","# Abstract\n## Purpose\n## Materials and methods\n## Results\n## Conclusions\n# Background\n## Clinical context of Ki67 in ER+/HER2- breast cancer\n## Role of diffusion-weighted MRI","[{\"question\":\"What is the purpose of distinguishing Ki67 stratification expression in ER+/HER2- breast cancer?\",\"answer\":\"Ki67 stratification guides clinical treatment strategy decisions and helps predict patient outcomes. The study focuses on improving diagnostic discrimination of Ki67 expression levels using MRI-derived features.\"},{\"question\":\"How were patients grouped by Ki67 expression in this study?\",\"answer\":\"Patients were pathologically categorized into low (≤5%, n=30), medium (\\u003e5% to \\u003c30%, n=41), and high Ki67 expression groups (≥30%, n=50).\"},{\"question\":\"Which MRI-based model showed the best performance for identifying low Ki67 expression?\",\"answer\":\"The FROC model constructed by D10%, µ90% and µSkewness achieved optimal diagnostic efficacy (AUC=0.858) and outperformed the conventional DWI model for low Ki67 discrimination.\"}]","Distinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers - comparison of advanced MRI diffusion models | PDF",1790090864,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b41d403964dad3d6210de86110ae0f8.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9ab688f8c0bdfb74aa316d5103f391f.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2afbd05ed22bddb81704a5c314864f9.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df14685a8f348fa15224e271dc25682e.webp",980,1306]